hkex

Latest Data of InnoCares Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)

December 08, 2025 21:04 ET  | Source: InnoCare Pharma BEIJING, Dec. 08, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969;…

1 week ago

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment…

2 weeks ago

InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis

BEIJING, Nov. 27, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the…

3 weeks ago

Fangzhou Awarded Golden Bull Award for Leadership in AI-Powered Chronic Disease Management

XIAMEN, China, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of…

1 month ago

SERES Officially Listed on HKEX, Leveraging Dual “A+H” Capital Platforms to Power Global Expansion

CHONGQING, China, Nov. 6, 2025 /PRNewswire/ -- On November 5, SERES Group (stock code: 9927.HK) was officially listed on the…

1 month ago

Fangzhous XingJie LLM Completes Key National Filing, Setting Stage for Further AI-Driven Chronic Care Innovations

SHENZHEN, China, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leader in AI-driven…

2 months ago

Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025

October 29, 2025 20:00 ET  | Source: ASCENTAGE PHARMA GROUP INTERNATIONAL ROCKVILLE, Md. and SUZHOU, China, Oct. 29, 2025 (GLOBE…

2 months ago

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025

September 04, 2025 20:00 ET  | Source: HUTCHMED (China) Limited HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 05,…

3 months ago

NOAH Holdings | ARK Wealth H2 CIO Report: Technology-Driven Deflation and Efficiency Dividends Are Reshaping Asset Allocation

The Report explores a dual-track economic structure, balancing structural inflation with deep deflation driven by technological disruption.Technology-driven deflation is projected…

4 months ago

HUTCHMED to Announce 2025 Half-Year Financial Results

July 03, 2025 04:30 ET  | Source: HUTCHMED (China) Limited HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 03,…

6 months ago
Show more Posts